Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Harvard Business School
McKinsey
Boehringer Ingelheim
Mallinckrodt

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Opicapone

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Opicapone: Patents, clinical trial progress, indications

Opicapone is an investigational drug.

There have been 30 clinical trials for Opicapone. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2016.

The most common disease conditions in clinical trials are Parkinson Disease and [disabled in preview]. The leading clinical trial sponsors are Bial - Portela C S.A., Rabin Medical Center, and Neurocrine Biosciences.

There are thirteen US patents protecting this investigational drug and one hundred and thirty-five international patents.

Recent Clinical Trials for Opicapone
TitleSponsorPhase
Relative Bioavailability and Bioequivalence of OpicaponeBial - Portela C S.A.Phase 1
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.Neurocrine BiosciencesPhase 1
Bioavailability and Bioequivalence Study of Two Different Sources of OpicaponeBial - Portela C S.A.Phase 1

See all Opicapone clinical trials

Clinical Trial Summary for Opicapone

Top disease conditions for Opicapone
Top clinical trial sponsors for Opicapone

See all Opicapone clinical trials

US Patents for Opicapone

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Opicapone   Start Trial Administration regime for nitrocatechols BIAL-PORTELA & CA, S.A. (Sao Mamede do Coronado, PT)   Start Trial
Opicapone   Start Trial Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof LobSor Pharmaceuticals Aktiebolag (Knivsta, SE)   Start Trial
Opicapone   Start Trial Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof BIAL--Portela & CA, S.A. (Sao Mamede do Coronado, PT)   Start Trial
Opicapone   Start Trial Nitrocatechol derivatives as COMT inhibitors Portela & CA., S.A. (S. Mamede do Coronado, PT)   Start Trial
Opicapone   Start Trial Dosage regimen for COMT inhibitors Bial-Portela & Ca., S.A. (S. Mamede do Coronado, PT)   Start Trial
Opicapone   Start Trial Nitrocatechol derivatives as COMT inhibitors Bial-Portela & Ca, S.A. (S. Mamede do Coronado, PT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Opicapone

Drugname Country Document Number Estimated Expiration Related US Patent
Opicapone Australia 2011358842 2031-02-11   Start Trial
Opicapone Brazil 112013007380 2031-02-11   Start Trial
Opicapone Canada 2826080 2031-02-11   Start Trial
Opicapone European Patent Office 2672973 2031-02-11   Start Trial
Opicapone Japan 2014505096 2031-02-11   Start Trial
Opicapone Japan 2017071619 2031-02-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Colorcon
Merck
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.